胰高血糖素样肽1受体激动剂相关的消化系统不良反应综述

卢春晓; 路长飞; 张华琦; 刘文文; 崔小康

doi:10.6039/j.issn.1001-0408.2024.12.22

您当前的位置：

首页 >

文章列表页 >

胰高血糖素样肽1受体激动剂相关的消化系统不良反应综述

综述 | 更新时间：2024-06-25

- 胰高血糖素样肽1受体激动剂相关的消化系统不良反应综述
- Adverse reactions of the digestive system caused by glucagon-like peptide-1 receptor agonists
- 中国药房 2024年35卷第12期页码：1539-1544
- 作者机构：
  
  1.山东大学齐鲁医学院，济南　250012
  2.山东省药品不良反应监测中心，济南　250013
- 作者简介：
  
  医师，硕士。研究方向：消化道肿瘤及代谢性疾病。E-mail：201900411083@mail.sdu.edu.cn
  副主任药师，硕士。研究方向：药品不良反应监测。E-mail：1694327715@qq.com
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.12.22
  中图分类号： R977.1+5;R587.1
- 纸质出版日期：2024-06-30，
  
  收稿日期：2024-01-31，
  
  修回日期：2024-05-13，
扫描看全文
卢春晓,路长飞,张华琦等.胰高血糖素样肽1受体激动剂相关的消化系统不良反应综述[J].中国药房,2024,35(12):1539-1544.

LU Chunxiao,LU Changfei,ZHANG Huaqi,et al.Adverse reactions of the digestive system caused by glucagon-like peptide-1 receptor agonists[J].ZHONGGUO YAOFANG,2024,35(12):1539-1544.
卢春晓,路长飞,张华琦等.胰高血糖素样肽1受体激动剂相关的消化系统不良反应综述[J].中国药房,2024,35(12):1539-1544. DOI： 10.6039/j.issn.1001-0408.2024.12.22.

LU Chunxiao,LU Changfei,ZHANG Huaqi,et al.Adverse reactions of the digestive system caused by glucagon-like peptide-1 receptor agonists[J].ZHONGGUO YAOFANG,2024,35(12):1539-1544. DOI： 10.6039/j.issn.1001-0408.2024.12.22.

摘要

胰高血糖素样肽1受体激动剂（GLP-1RAs）近年来广泛应用于糖尿病和肥胖人群，同时也引起了一系列不良反应，其中最重要的是消化系统不良反应。GLP-1RAs相关的消化系统不良反应涉及胃肠道、胰腺和胆道，其中恶心、呕吐、便秘、腹泻发生率较高，是导致患者停药的主要原因。胰腺和胆道系统疾病的发病率较低，但尚无研究证据可排除其与GLP-1RAs的关联。替尔泊肽上市较晚，其安全性尚缺乏足够的真实世界数据。医护人员应对患者采用积极的饮食指导策略，并加强用药教育，以帮助患者积极预防、科学应对GLP-1RAs相关的消化系统不良反应的发生。

Abstract

Glucagon-like peptide-1 receptor agonists （GLP-1RAs） have been widely used in diabetes and obese people in recent years， and they have also caused a series of adverse reactions， the most important of which is digestive system-related adverse reactions. The adverse reactions of the digestive system associated with GLP-1RAs involve the gastrointestinal， pancreatic， and biliary tracts； among them， nausea， vomiting， constipation， and diarrhea are the most common adverse reactions， which are the main reasons for drug withdrawal. The incidence of pancreatic and biliary system diseases is low， but there is no research evidence to exclude their association with GLP-1RAs. Tirzepatide appears on the market relatively late， and its safety still lacks sufficient real-world data. Medical staff should adopt active dietary guidance strategies for patients and strengthen medication education to help patients actively prevent and scientifically respond to adverse reactions in the digestive system.

关键词

胰高血糖素样肽1受体激动剂消化系统不良反应

Keywords

digestive systemadverse reaction

references

LYSENG-WILLIAMSON K A. Glucagon-like peptide-1 receptor analogues in type 2 diabetes：their use and diffe-rential features[J]. Clin Drug Investig，2019，39（8）：805-819.

RUBINO D M，GREENWAY F L，KHALID U，et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes：the STEP 8 randomized clinical trial[J]. JAMA，2022，327（2）：138-150.

WHARTON S，CALANNA S，DAVIES M，et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity，and the relationship between gastrointestinal adverse events and weight loss[J]. Diabetes Obes Metab，2022，24（1）：94-105.

GORGOJO-MARTÍNEZ J J，MEZQUITA-RAYA P，CARRETERO-GÓMEZ J，et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists：a multidisciplinary expert consensus[J]. J Clin Med，2022，12（1）：145.

SODHI M，REZAEIANZADEH R，KEZOUH A，et al. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss[J]. JAMA，2023，330（18）：1795-1797.

HOLST J J. The physiology of glucagon-like peptide 1[J]. Physiol Rev，2007，87（4）：1409-1439.

JASTREBOFF A M，ARONNE L J，AHMAD N N，et al. Tirzepatide once weekly for the treatment of obesity[J]. N Engl J Med，2022，387（3）：205-216.

ANDERSEN A，KNOP F K，VILSBØLL T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes[J]. Drugs，2021，81（9）：1003-1030.

MEIER J J. Efficacy of semaglutide in a subcutaneous and an oral formulation[J]. Front Endocrinol，2021，12：645617.

LINNEBJERG H，PARK S，KOTHARE P A，et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes[J]. Regul Pept，2008，151（1/2/3）：123-129.

JUHL C B，HOLLINGDAL M，STURIS J，et al. Bedtime administration of NN2211，a long-acting GLP-1 derivative，substantially reduces fasting and postprandial glycemia in type 2 diabetes[J]. Diabetes，2002，51（2）：424-429.

RAYNER C K，SAMSOM M，JONES K L，et al. Relationships of upper gastrointestinal motor and sensory function with glycemic control[J]. Diabetes Care，2001，24（2）：371-381.

SMITS M M，TONNEIJCK L，MUSKIET M H，et al. Ga-strointestinal actions of glucagon-like peptide-1-based therapies：glycaemic control beyond the pancreas[J]. Diabetes Obes Metab，2016，18（3）：224-235.

THAZHATH S S，MARATHE C S，WU T Z，et al. The glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility，flow，transit，and absorption of glucose in healthy subjects and patients with type 2 diabetes：a randomized controlled trial[J]. Diabetes，2016，65（1）：269-275.

DEGN K B，JUHL C B，STURIS J，et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide（NN2211）markedly improves 24 h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes[J]. Diabetes，2004，53（5）：1187-1194.

VAN BLOEMENDAAL L，TEN KULVE J S，LA FLEUR S E，et al. Effects of glucagon-like peptide 1 on appetite and body weight：focus on the CNS[J]. J Endocrinol，2014，221（1）：T1-T16.

NAUCK M A，QUAST D R，WEFERS J，et al. GLP-1 receptor agonists in the treatment of type 2 diabetes：state-of-the-art[J]. Mol Metab，2021，46：101102.

SMITS M M，VAN RAALTE D H. Safety of semaglutide[J]. Front Endocrinol，2021，12：645563.

O’NEIL P M，BIRKENFELD A L，MCGOWAN B，et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity：a randomised，double-blind，placebo and active controlled，dose-ranging，phase 2 trial[J]. Lancet，2018，392（10148）：637-649.

NAUCK M A，MEIER J J. Management of endocrine disease：are all GLP-1 agonists equal in the treatment of type 2 diabetes?[J]. Eur J Endocrinol，2019，181（6）：R211-R234.

BELLIDO D，ABELLÁN P，RUIZ PALOMAR J M，et al. Intensification of basal insulin therapy with lixisenatide in patients with type 2 diabetes in a real-world setting：the BASAL-LIXI study[J]. Curr Ther Res Clin Exp，2018，89：37-42.

WADDEN T A，BAILEY T S，BILLINGS L K，et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity：the STEP 3 randomized clinical trial[J]. JAMA，2021，325（14）：1403-1413.

GUDIN B，LADHARI C，ROBIN P，et al. Incretin-based drugs and intestinal obstruction：a pharmacovigilance study[J]. Therapie，2020，75（6）：641-647.

KALAS M A，GALURA G M，MCCALLUM R W. Medication-induced gastroparesis：a case report[J]. J Investig Med High Impact Case Rep，2021，9：23247096211051919.

HOROWITZ M，ARODA V R，HAN J，et al. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists：incidence and consequences[J]. Diabetes Obes Metab，2017，19（5）：672-681.

KANOSKI S E，RUPPRECHT L E，FORTIN S M，et al. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists，exendin-4 and liraglutide[J]. Neuropharmacology，2012，62（5/6）：1916-1927.

BORNER T，WORKINGER J L，TINSLEY I C，et al. Corrination of a GLP-1 receptor agonist for glycemic control without emesis[J]. Cell Rep，2020，31（11）：107768.

GABERY S，SALINAS C G，PAULSEN S J，et al. Semaglutide lowers body weight in rodents via distributed neural pathways[J]. JCI Insight，2020，5（6）：e133429.

HJERPSTED J B，FLINT A，BROOKS A，et al. Semaglutide improves postprandial glucose and lipid metabolism，and delays first-hour gastric emptying in subjects with obesity[J]. Diabetes Obes Metab，2018，20（3）：610-619.

FRIEDRICHSEN M，BREITSCHAFT A，TADAYON S，et al. The effect of semaglutide 2.4 mg once weekly on energy intake，appetite，control of eating，and gastric emp-tying in adults with obesity[J]. Diabetes Obes Metab，2021，23（3）：754-762.

GUTZWILLER J P，HRUZ P，HUBER A R，et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans[J]. Digestion，2006，73（2/3）：142-150.

WEGEBERG A L，HANSEN C S，FARMER A D，et al. Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy：a randomised，double-blind，placebo-controlled trial[J]. United European Ga-stroenterol J，2020，8（6）：695-704.

YANG Z，LV Y H，YU M，et al. GLP-1 receptor agonist-associated tumor adverse events：a real-world study from 2004 to 2021 based on FAERS[J]. Front Pharmacol，2022，13：925377.

TRUJILLO J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes[J]. J Clin Pharm Ther，2020，45（Suppl. 1）：43-60.

NREU B，DICEMBRINI I，TINTI F，et al. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists：an updated meta-analysis of randomized controlled trials[J]. Minerva Endocrinol，2023，48（2）：206-213.

ARODA V R，ABERLE J，BARDTRUM L，et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes（PIONEER PLUS）：a multicentre，randomised，phase 3b trial[J]. Lancet，2023，402（10403）：693-704.

NYBORG N C，MØLCK A M，MADSEN L W，et al. The human GLP-1 analog liraglutide and the pancreas：evidence for the absence of structural pancreatic changes in three species[J]. Diabetes，2012，61（5）：1243-1249.

GIER B，MATVEYENKO A V，KIRAKOSSIAN D，et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the KRAS（G12D）mouse model[J]. Diabetes，2012，61（5）：1250-1262.

MONAMI M，NREU B，SCATENA A，et al. Safety issues with glucagon-like peptide-1 receptor agonists（pancreatitis，pancreatic cancer and cholelithiasis）：data from randomized controlled trials[J]. Diabetes Obes Metab，2017，19（9）：1233-1241.

HE L Y，WANG J L，PING F，et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases：a systematic review and meta-analysis of randomized clinical trials[J]. JAMA Intern Med，2022，182（5）：513-519.

NAUCK M A，MUUS GHORBANI M L，KREINER E，et al. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial[J]. Diabetes Care，2019，42（10）：1912-1920.

SMITS M M，TONNEIJCK L，MUSKIET M H，et al. Bi-liary effects of liraglutide and sitagliptin，a 12-week randomized placebo-controlled trial in type 2 diabetes patients[J]. Diabetes Obes Metab，2016，18（12）：1217-1225.

MARZIONI M，ALPINI G，SACCOMANNO S，et al. Exendin-4，a glucagon-like peptide 1 receptor agonist， protects cholangiocytes from apoptosis[J]. Gut，2009，58（7）：990-997.

COSKUN T，SLOOP K W，LOGHIN C，et al. LY3298176，a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus：from discovery to clinical proof of concept[J]. Mol Metab，2018，18：3-14.

FRÍAS J P，DAVIES M J，ROSENSTOCK J，et al. Tir-zepatide versus semaglutide once weekly in patients with type 2 diabetes[J]. N Engl J Med，2021，385（6）：503-515.

BETTGE K，KAHLE M，ABD EL AZIZ M S，et al. Occur-rence of nausea，vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists：a systematic analysis of published clinical trials[J]. Diabetes Obes Metab，2017，19（3）：336-347.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

阿帕替尼血药浓度测定方法的建立及临床应用

抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展

奥马珠单抗治疗儿童过敏性疾病的安全性分析

不同肠内营养制剂用于重症急性胰腺炎的疗效及胃肠道耐受性研究

替加环素致严重肾功能不全患者凝血功能异常的回顾性分析